Sensyne Health welcomes UK government announcement today endorsing the potential of analysing anonymised NHS patient data in an ethical way to improve patient care and accelerate medical research

Sensyne is working with a set of experts with the requisite capabilities in computing, data analytics and systems integration to deliver such a strategy.

Read more
Sensyne Health signs Strategic Advisory Services agreement with EY

EY to support Sensyne’s mission to increase capacity to curate and analyse large numbers of anonymised datasets as it develops a global approach to the valuation of patient medical data

Read more
Official product launch of GDm-Health™

Regulated, cloud-based digital therapeutic product for the management of gestational diabetes, is commercially available for use across the NHS. Five NHS Trusts have signed contracts to use GDm-Health.

Read more
Board Appointment: Professor Lionel Tarassenko Appointed as Non-Executive Director and Director of R&D

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announces the appointment of Professor Lionel Tarassenko CBE FREng FMedSci as Director of Research & Development and Non-Executive Director of the Board, with immediate effect.

Read more
Sensyne Health licenses Privitar’s data privacy software

Sensyne Health plc announces it has signed a three year strategic agreement with Privitar to license its de-identification and privacy protection software.

Read more
Sensyne Health welcomes and commits to new government code of conduct for data-driven health and care technologies

Sensyne Health plc (LSE: SENS) (the “Company”), the British clinical AI technology company, today welcomes and signs up to the Department of Health and Social Care’s (DHSC) new code of conduct for data-driven health and care technologies.

Read more
Sensyne Health plc Admission to trading on AIM and First Day of Dealings

Sensyne Health plc (“Sensyne Health” or the “Company”), a British clinical artificial intelligence company, is pleased to announce that its ordinary shares have today been admitted to trading on the AIM market of the London Stock Exchange under the ticker SENS ("Admission") and ISIN GB00BYV3J755.

Read more
Sensyne Health plc Placing and Proposed Admission to trading on AIM

Sensyne Health plc (“Sensyne Health” or the “Company”), a British healthcare technology company, announces it has successfully raised £60 million in its initial public offering (the “IPO”) through a placing (the “Placing”). Peel Hunt LLP (“Peel Hunt”) is acting as Bookrunner in connection with the Placing and Nominated Adviser and Broker to the Company.

Read more
Sensyne Health acquires digital health software product for the treatment of heart failure developed by The George Institute for Global Health at the University of Oxford and Oxford University Hospitals NHS Foundation Trust

Support-HF product will support patients and clinicians in managing heart failure and curate data for medical research using Clinical AI

Read more
Sensyne Health signs Strategic Research Agreement with Oxford University Hospitals NHS Foundation Trust

New research collaboration aims to analyse anonymised genetic data using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.

Read more
Sensyne Health and Chelsea and Westminster Hospital NHS Foundation Trust sign Strategic Research Agreement

New agreement enables analysis of anonymised patient data using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.

Read more
Sensyne Health signs Strategic Research Agreement with South Warwickshire NHS Foundation Trust

New research collaboration aims to analyse anonymised patient data across community and acute care using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.

Read more
Drayson Health signs Memorandum of Understanding with South Warwickshire NHS Foundation Trust

New relationship aims to combine access to anonymised patient data with clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care.

Read more
Drayson Health welcomes Prime Minister’s comments on the promise of AI

Commits to supporting government plans in partnership with leading UK academics and NHS Trusts to significantly reduce deaths from chronic diseases using its clinical artificial intelligence tools and expertise

Read more
Professor David Clifton joins Drayson Health as Research Director

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Read more
Positive Clinical Trial of GDm-Health™

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes.

Read more
CleanSpace recognised in UK Government CMO’s report

Digital healthcare company Drayson Health, welcomes the inclusion of CleanSpaceTM, a system for monitoring exposure to air pollution.

Read more
Digital Health Partnership Wins Collaboration Award

A ground-breaking partnership comprising the University of Oxford, Oxford University Innovation, Oxford University Hospitals NHS Foundation Trust and Drayson Technologies has won the 2017 Oxford Academic Health Science Network Best Public-Private Collaboration Award.

Read more
Chelsea and Westminster Hospital partner with Drayson Health

In what is a global healthcare first, a major NHS Foundation Trust will pilot wireless environmental sensors in their intensive care units.

Read more
GDm-Health Published on NHS Digital Tools Library

The GDm-Health™ app, for the management of women gestational diabetes, has been recommended for publication in the NHS Digital Tools Library, following an extensive review as part of the NHS Digital technical review process.

Read more
Drayson Technologies Agrees Digital Health Deal

Millions of NHS patients are set to benefit from a landmark licensing deal between Drayson Technologies and a partnership between the University of Oxford and Oxford University Hospitals NHS Foundation Trust.

Read more

Oxford Office

Schrödinger Building,
Heatley Road, Oxford Science Park,
Oxford, OX4 4GE

Schrödinger Building,
Heatley Road, Oxford Science Park,
Oxford, OX4 4GE

+44 (0) 330 058 1845

Contact us

For press enquiries, please contact press@sensynehealth.com